Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
|Articles|October 1, 2012
Contemporary Pediatrics, Digital Edition, October 2012
New designer drugs : Legal, available, deadly Etiologies of infectious mononucleosis Unique sleep needs of teenagers Puzzler : Abnormal, fidgety movements in young girl Dermcase : New virus causes fever, rash
Advertisement
Advertisement
Related to this article
More than half of firearm-owning parents of children aged 1 to 5 years reported at least 1 firearm stored unlocked, loaded, or both.
The Autus Size-Adjustable Valve can be implanted at about 13 mm and balloon-expanded to 22 mm as children grow, with no deaths or strokes among 62 patients studied.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
AAP’s 2026 conference will bring pediatricians updates on AI, vaccines, misinformation, nutrition, mental health, and clinical care.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Upadacitinib sustains repigmentation in non-segmental vitiligo through 76 weeks
2
BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy
3
FDA approves expandable Autus valve for congenital pulmonary valve disease
4
FDA news in pediatrics: September 2026
5